Rowan T Chlebowski

Summary

Publications

  1. pmc Changing concepts: Menopausal hormone therapy and breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    J Natl Cancer Inst 104:517-27. 2012
  2. doi request reprint Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA, 90502, USA
    Breast Cancer Res Treat 161:185-190. 2017
  3. pmc Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial
    R T Chlebowski
    Affiliations of authors Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA GLA, AKA, CC Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA GES, SDR Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA RH Herbert Wertheim College of Medicine Florida International University, Miami, FL CDR Department of Nutritional Sciences and Arizona Cancer Center, University of Arizona, Tucson, AZ CAT Star Research Institute Howard University, Washington, DC BVH Department of Social and Preventive Medicine, State University of New York, Memphis, TN JWW Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY TER Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI MSS Brigham and Women s Health Hospital, Harvard Medical School, Boston, MA JEM
    J Natl Cancer Inst 108:. 2016
  4. doi request reprint Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA GLA, AKA, RP
    J Natl Cancer Inst 108:. 2016
  5. doi request reprint Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity
    R T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Breast Cancer Res Treat 154:609-16. 2015
  6. doi request reprint Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA Electronic address
    Clin Lung Cancer 17:10-7.e1. 2016
  7. pmc Menopausal hormone therapy and cancer: changing clinical observations of target site specificity
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, United States Electronic address
    Steroids 90:53-9. 2014
  8. doi request reprint Adherence to endocrine therapy in breast cancer adjuvant and prevention settings
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, 1124 W Carson Street, Bldg J3, Torrance, CA 90502
    Cancer Prev Res (Phila) 7:378-87. 2014
  9. doi request reprint Nutrition and physical activity influence on breast cancer incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Building J 3, Torrance, CA 90502, USA Electronic address
    Breast 22:S30-7. 2013
  10. pmc Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Menopause 20:600-8. 2013

Detail Information

Publications96

  1. pmc Changing concepts: Menopausal hormone therapy and breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    J Natl Cancer Inst 104:517-27. 2012
    ..Currently, the different effects of estrogen plus progestin vs estrogen alone on breast cancer are not completely understood...
  2. doi request reprint Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA, 90502, USA
    Breast Cancer Res Treat 161:185-190. 2017
    ..Therefore, we performed a systematic literature review and meta-analysis of relevant randomized trials...
  3. pmc Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial
    R T Chlebowski
    Affiliations of authors Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA GLA, AKA, CC Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA GES, SDR Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA RH Herbert Wertheim College of Medicine Florida International University, Miami, FL CDR Department of Nutritional Sciences and Arizona Cancer Center, University of Arizona, Tucson, AZ CAT Star Research Institute Howard University, Washington, DC BVH Department of Social and Preventive Medicine, State University of New York, Memphis, TN JWW Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY TER Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI MSS Brigham and Women s Health Hospital, Harvard Medical School, Boston, MA JEM
    J Natl Cancer Inst 108:. 2016
    ..These issues were assessed by analyses after extended follow-up of the Women's Health Initiative (WHI) randomized clinical trial evaluating continuous combined estrogen plus progestin use...
  4. doi request reprint Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA GLA, AKA, RP
    J Natl Cancer Inst 108:. 2016
    ..Therefore, observational studies should not combine these two regimens when examining breast cancer risk. ..
  5. doi request reprint Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity
    R T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Breast Cancer Res Treat 154:609-16. 2015
    ..Using a benefit/risk index for endocrine adjuvant breast cancer therapy in postmenopausal women, benefit was higher for aromatase inhibitor use in almost all circumstances. ..
  6. doi request reprint Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA Electronic address
    Clin Lung Cancer 17:10-7.e1. 2016
    ..71; 95% confidence interval [CI], 1.16-2.52; P = .01). Now after 14 years' median follow-up, we reexamined combined hormone therapy effects on lung cancer mortality...
  7. pmc Menopausal hormone therapy and cancer: changing clinical observations of target site specificity
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, United States Electronic address
    Steroids 90:53-9. 2014
    ..These complex results are discussed in the context of known potential mediating mechanisms of action involved in interaction with steroid hormone receptors. ..
  8. doi request reprint Adherence to endocrine therapy in breast cancer adjuvant and prevention settings
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, 1124 W Carson Street, Bldg J3, Torrance, CA 90502
    Cancer Prev Res (Phila) 7:378-87. 2014
    ....
  9. doi request reprint Nutrition and physical activity influence on breast cancer incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Building J 3, Torrance, CA 90502, USA Electronic address
    Breast 22:S30-7. 2013
    ..To provide a current perspective on nutrition and physical activity influence on breast cancer...
  10. pmc Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Menopause 20:600-8. 2013
    ..Against this background, estrogen-alone effects on joint symptoms were examined in post hoc analyses in the Women's Health Initiative randomized, placebo-controlled, clinical trial...
  11. pmc Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA
    J Natl Cancer Inst 105:526-35. 2013
    ..To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied...
  12. pmc Diabetes, metformin, and breast cancer in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Clin Oncol 30:2844-52. 2012
    ..Therefore, we assessed associations among diabetes, metformin use, and breast cancer in postmenopausal women participating in Women's Health Initiative clinical trials...
  13. pmc Genetic variants in the MRPS30 region and postmenopausal breast cancer risk
    Ying Huang
    Fred Hutchinson Cancer Research Center, Divisions of Public Health Sciences, and Vaccine and Infectious Diseases, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Genome Med 3:42. 2011
    ..Genotype by environment interactions may contribute further to such explanation, and may help to refine the genomic regions of interest...
  14. pmc Estrogen and progesterone-related gene variants and colorectal cancer risk in women
    Jennifer H Lin
    Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    BMC Med Genet 12:78. 2011
    ..Inherited variation in the sex-hormone genes may be one mechanism by which sex hormones affect colorectal cancer, although data are limited...
  15. pmc Vitamin D and breast cancer: interpreting current evidence
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 11243 West Carson Street, Torrance, CA 90502, USA
    Breast Cancer Res 13:217. 2011
    ..Current evidence supports the pursuit of several research questions but not routine 25-hydroxyvitamin D monitoring and vitamin D supplementation to reduce breast cancer incidence or improve breast cancer outcome...
  16. pmc Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer
    Ross L Prentice
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 18:3079-85. 2009
    ..Single nucleotide polymorphisms (SNP) in the fibroblast growth factor receptor 2 (FGFR2) gene are substantially associated with postmenopausal breast cancer risk and could influence hormone therapy effects...
  17. pmc Calcium plus vitamin D supplementation and the risk of breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Natl Cancer Inst 100:1581-91. 2008
    ..Although some observational studies have associated higher calcium intake and especially higher vitamin D intake and 25-hydroxyvitamin D levels with lower breast cancer risk, no randomized trial has evaluated these relationships...
  18. ncbi request reprint Predicting risk of breast cancer in postmenopausal women by hormone receptor status
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA
    J Natl Cancer Inst 99:1695-705. 2007
    ..We evaluated and attempted to improve the performance of the Breast Cancer Risk Assessment Tool (i.e., the Gail model) for estimating invasive breast cancer risk by receptor status in postmenopausal women...
  19. pmc Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials
    JoAnn E Manson
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    JAMA 310:1353-68. 2013
    ..Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention...
  20. pmc Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study
    Christopher I Li
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 102:1422-31. 2010
    ..This association is thought to be largely hormonally driven, so alcohol use may be more strongly associated with hormonally sensitive breast cancers. Few studies have evaluated how alcohol-related risk varies by breast cancer subtype...
  21. pmc Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California Los Angeles, 1124 W Carson St, Torrance, CA 90502, USA
    J Clin Oncol 28:2690-7. 2010
    ..625 mg/d) or placebo...
  22. pmc Estrogen plus progestin and risk of benign proliferative breast disease
    Thomas E Rohan
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cancer Epidemiol Biomarkers Prev 17:2337-43. 2008
    ..76 (95% CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease...
  23. pmc Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    JAMA 304:1684-92. 2010
    ..7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported...
  24. pmc Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer
    Amanda I Phipps
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 103:470-7. 2011
    ..Hormonally mediated risk factors may be differentially related to risk of triple-negative and ER+ breast cancers...
  25. pmc Estrogen plus progestin therapy and breast cancer in recently postmenopausal women
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:1207-16. 2008
    ..64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use...
  26. doi request reprint Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial
    Thomas E Rohan
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA
    J Natl Cancer Inst 100:563-71. 2008
    ..We tested the effect of conjugated equine estrogen (CEE) on risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial...
  27. pmc Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, PO Box 19024, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 99:1534-43. 2007
    ..The trial protocol also listed ovarian cancer and endometrial cancer as outcomes that may be favorably affected by the intervention...
  28. pmc Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:1407-15. 2008
    ....
  29. doi request reprint Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cancer Causes Control 22:1415-24. 2011
    ..The contribution of menstrual and reproductive factors to risk of ductal carcinoma (DCIS) of the breast is poorly understood...
  30. pmc Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial
    Andrea Z LaCroix
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3 A410, PO 19024, Seattle, WA 98109
    JAMA 305:1305-14. 2011
    ..1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned trial termination date. Postintervention health outcomes have not been reported...
  31. pmc Estrogen plus progestin and colorectal cancer incidence and mortality
    Michael S Simon
    Karmanos Cancer Institute, Wayne State University, Hudson Webber Cancer Research Building, 4221 HWCRC, 4100 John R, Detroit, MI 48201, USA
    J Clin Oncol 30:3983-90. 2012
    ..To assess the clinical relevance of the findings, analyses of the influence of combined hormone therapy on colorectal cancer incidence and colorectal cancer mortality were conducted after extended follow-up...
  32. pmc Sex hormone levels and risk of breast cancer with estrogen plus progestin
    Ghada N Farhat
    Affiliations of authors San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA GNF, NP, SRC Faculty of Health Sciences, University of Balamand, Beirut, Lebanon GNF Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA JEM Fred Hutchinson Cancer Research Center, Seattle, WA GA, AZL Department of Internal Medicine, University of California San Francisco, San Francisco, CA AH, DG Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA EV Department of Internal Medicine, University of California Davis, Sacramento, CA JSL Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA JAC Department of Internal Medicine, Ohio State University, Columbus, OH RJ Department of Preventive Medicine, Stony Brook University, Stony Brook, NY DL Department of Medicine, Emory University, Atlanta, GA LP Karmanos Cancer Institute, Wayne State University, Detroit, MI MSS
    J Natl Cancer Inst 105:1496-503. 2013
    ..Although high endogenous sex hormone levels and estrogen plus progestin (E+P) therapy are associated with increased breast cancer risk, it is unknown whether pretreatment levels of sex hormones modify E+P effect on breast cancer...
  33. pmc Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Natl Cancer Inst 102:1413-21. 2010
    ..We conducted post hoc analyses in the WHI trial evaluating estrogen alone to determine whether use of conjugated equine estrogen without progestin had a similar adverse influence on lung cancer...
  34. doi request reprint Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
    Cancer Causes Control 21:2173-81. 2010
    ..To assess the association of recreational physical activity and anthropometric factors in relation to risk of ductal carcinoma in situ (DCIS) of the breast...
  35. pmc Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study
    Ross L Prentice
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 18:1531-7. 2009
    ..Here, data from the WHI observational study are considered, in conjunction with colorectal cancer mortality data from the hormone therapy trials, in an attempt to clarify postmenopausal hormone therapy effects...
  36. pmc Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Lancet 374:1243-51. 2009
    ..To assess whether such an association exists, we undertook a post-hoc analysis of lung cancers diagnosed in the trial over the entire follow-up period...
  37. pmc Breast cancer after use of estrogen plus progestin in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    N Engl J Med 360:573-87. 2009
    ..Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial...
  38. pmc Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial
    Garnet L Anderson
    Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA 98109, USA
    Lancet Oncol 13:476-86. 2012
    ..We aimed to assess the influence of oestrogen use on longer term breast cancer incidence and mortality in extended follow-up of this cohort...
  39. pmc Oral bisphosphonate use and breast cancer incidence in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Clin Oncol 28:3582-90. 2010
    ..Emerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence...
  40. pmc Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer
    Amanda I Phipps
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M4 B402, P O Box 19024, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 20:454-63. 2011
    ..Focusing on potentially modifiable breast cancer risk factors, we examined the relationship between body size, physical activity, and triple-negative disease risk...
  41. pmc Diabetes, metformin use, and colorectal cancer survival in postmenopausal women
    Furha Iram Cossor
    Tufts Medical Center, 800 Washington Street, Box 245, Boston, MA 02111, USA
    Cancer Epidemiol 37:742-9. 2013
    ..We examined the relationships among metformin use, diabetes, and survival in postmenopausal women with CRC in the Women's Health Initiative (WHI) clinical trials and observational study...
  42. doi request reprint Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Arch Intern Med 168:370-7; quiz 345. 2008
    ..The effect of combined hormone therapy on breast cancer detection is not established...
  43. pmc Vitamin D intake and lung cancer risk in the Women's Health Initiative
    Ting Yuan David Cheng
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA and Biostatistics, University of Washington, Seattle, WA Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA
    Am J Clin Nutr 98:1002-11. 2013
    ..Prior research suggests that vitamin D protects against lung cancer only among certain subgroups...
  44. pmc Migraine history and breast cancer risk among postmenopausal women
    Christopher I Li
    Fred Hutchinson Cancer Research Center, 1100 N Fairview Ave, M4 C308, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:1005-10. 2010
    ..06). CONCLUSION This study supports the hypothesis that a history of migraine is associated with a lower risk of breast cancer and that this relationship is independent of recent NSAID use...
  45. ncbi request reprint Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial
    Anne McTiernan
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
    J Natl Cancer Inst 97:1366-76. 2005
    ..Increased mammographic density reduces the sensitivity of screening mammography, is associated with increased breast cancer risk, and may be hormone related. We assessed the effect of estrogen-plus-progestin therapy on mammographic density...
  46. doi request reprint A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cancer Epidemiol Biomarkers Prev 18:2046-53. 2009
    ....
  47. pmc Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Am J Clin Nutr 90:162-9. 2009
    ..Prospective studies have examined the association of serum and plasma carotenoids and micronutrients and breast cancer; however, to date, studies have only assessed exposure at one point in time...
  48. pmc Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial
    Thomas E Rohan
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Cancer Prev Res (Phila) 1:275-84. 2008
    ..These results suggest that a modest reduction in fat intake and increase in fruit, vegetable, and grain intake do not alter the risk of benign proliferative breast disease...
  49. pmc A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease
    Thomas E Rohan
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Breast Cancer Res Treat 116:339-50. 2009
    ..Daily use of 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D(3) for almost 7 years by postmenopausal women did not alter the overall risk of benign proliferative breast disease...
  50. pmc 25-hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, United States
    Maturitas 68:73-8. 2011
    ..However, the results are mixed and few studies have evaluated associations between 25(OH) D concentrations and both total vitamin D intake and clinical joint symptoms...
  51. ncbi request reprint Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Shirley A A Beresford
    Department of Epidemiology, University of Washington, Seattle, WA 98195 7236, USA
    JAMA 295:643-54. 2006
    ..Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial...
  52. pmc Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls
    Kathy Pan
    Harbor UCLA Medical Center, Torrance, CA, USA
    Breast Cancer Res Treat 156:567-76. 2016
    ..Breast cancer survivors having only a clinically marginal increase in medication use compared to cancer-free controls. These findings highlight the importance of incorporation of control populations in studies of cancer survivorship...
  53. pmc Adipokines linking obesity with colorectal cancer risk in postmenopausal women
    Gloria Y F Ho
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 72:3029-37. 2012
    ..Hyperinsulinemia and hyperleptinemia may therefore partially explain the adiposity association with colorectal cancer in postmenopausal women...
  54. pmc Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial
    Anne McTiernan
    Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, M4 B874, PO Box 19024, Seattle, WA 98019, USA
    J Clin Oncol 27:6135-43. 2009
    ..We examined the effect of CEE alone on mammographic density in a subsample of the Women's Health Initiative (WHI) clinical trial participants...
  55. doi request reprint Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Int J Cancer 125:2704-10. 2009
    ..Analysis of the repeated measurements supported the results of the baseline analysis. These data suggest that elevated serum insulin levels may be a risk factor for postmenopausal breast cancer...
  56. pmc Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial
    Cheryl Ritenbaugh
    University of Arizona College of Medicine, Tucson, Arizona 85719, USA
    Cancer Epidemiol Biomarkers Prev 17:2609-18. 2008
    ..We now analyze features of the colorectal cancers that developed and examine the survival of women following colorectal cancer diagnosis in the latter trial...
  57. pmc Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative
    Jennifer C Livaudais
    Corresponding Author Jennifer C Livaudais, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 22:365-73. 2013
    ..Differences in breast cancer treatment likely play a role. Adjuvant hormonal therapies increase overall survival among women with hormone receptor-positive breast cancer...
  58. ncbi request reprint Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Barbara V Howard
    MedStar Research Institute Howard University, Washington, DC, USA
    JAMA 295:655-66. 2006
    ..Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed...
  59. doi request reprint Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, CA 90502, USA
    Breast J 18:299-302. 2012
    ..Thus, aromatase inhibitors, and perhaps particularly exemestane, provide an option to address the risk of contralateral breast cancer in postmenopausal women with DCIS managed with mastectomy...
  60. pmc Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk
    Marc J Gunter
    Imperial College, London, UK MJG Albert Einstein College of Medicine, Bronx, NY TW, XX, SWS, HDS, TER, RCK, DW, GYFH University of Vermont, Burlington, VT MC Brigham and Women s Hospital, Harvard Medical School, Boston, MA JEM Fred Hutchinson Cancer Research Center, Seattle, WA AM University of Texas Southwestern Medical School, Dallas, TX PES University of California Los Angeles, Torrence, CA RTC University of Iowa, Iowa City, IA LS
    J Natl Cancer Inst 107:. 2015
    ..Adipokines and inflammation may provide a mechanistic link between obesity and postmenopausal breast cancer, yet epidemiologic data on their associations with breast cancer risk are limited...
  61. doi request reprint Alcohol consumption and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cancer Epidemiol Biomarkers Prev 19:2066-72. 2010
    ..Observational studies have commonly linked higher alcohol consumption with a modest increase in invasive breast cancer risk, but cohort studies have not examined alcohol intake in relation to ductal carcinoma in situ (DCIS)...
  62. pmc Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative
    Michael S Simon
    Karmanos Cancer Institute, Department of Oncology, Detroit, MI, USA
    Cancer Epidemiol Biomarkers Prev 20:1368-78. 2011
    ..The women's health initiative (WHI) study sample was used to determine whether differences in CRC risk factors explain racial/ethnic differences in incidence and mortality...
  63. pmc Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older
    Mara A Schonberg
    Division of General Medicine and Primary Care, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA MAS, VWL, RBD, EPM, ERM, LHN Department of Epidemiology, Harvard School of Public Health, Boston, MA and Channing Division of Network Medicine, Brigham and Women s Hospital, Harvard Medical School, Harvard School of Public Health, Boston, MA AHE, Bar, SEH Division of Epidemiology, Family and Preventive Medicine, University of California San Diego, La Jolla, CA AZL Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA RTC Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY TER Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, MA SEH
    J Natl Cancer Inst 108:. 2016
    ..The Breast Cancer Risk Assessment Tool (BCRAT, "Gail model") is commonly used for breast cancer prediction; however, it has not been validated for women age 75 years and older...
  64. pmc Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer
    Elizabeth Maunsell
    Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire CHU de Québec, Axe Oncologie, Québec Pierre Dubé, Hopital Maisonneuve Rosemont, Montreal, QC Andrew L Cooke, CancerCare Manitoba, Winnipeg, MB Silvana Spadafora, Algoma District Cancer Program, Sault Ste Marie, ON Lavina Lickley, Women s College Hospital Angela M Cheung, University Health Network, University of Toronto, Toronto Dianne Johnston, Andrea Hiltz, Michael Brundage, Dongsheng Tu, and Harriet Richardson, National Cancer Institute of Canada Clinical Trials Group Joseph Pater, Queens University, Kingston, ON Susan L Ellard, British Columbia Cancer Agency Southern Interior, Kelowna Karen A Gelmon, British Columbia Cancer Agency, Vancouver, BC, Canada Paul E Goss, Massachusetts General Hospital, Boston, MA Rowan T Chlebowski, University of California at Los Angeles Medical Centre, Torrance, CA James N Ingle and Sandhya Pruthi, Mayo Clinic
    J Clin Oncol 32:1427-36. 2014
    ..3 (Mammary Prevention 3) trial, but effects on quality of life (QOL) were not fully described...
  65. ncbi request reprint Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast
    Yan Cui
    Office of Health Assessment and Epidemiology, Los Angeles County Department of Public Health, Los Angeles, CA, USA
    Int J Cancer 121:1346-51. 2007
    ..In conclusion, we observed that alcohol consumption and folate intake were not associated with altered risk of BPED, and that there was no effect modification between them in relation to the risk of BPED...
  66. pmc Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer
    Ross L Prentice
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, PO Box 19024, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 19:74-9. 2010
    ..Single nucleotide polymorphisms (SNP) in the FGFR2 gene relate strongly to breast cancer risk and could influence intervention effects...
  67. doi request reprint Exemestane for breast-cancer prevention in postmenopausal women
    Paul E Goss
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 364:2381-91. 2011
    ..Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer...
  68. doi request reprint Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California
    JAMA Oncol 1:296-305. 2015
    ..The use of menopausal hormone therapy (HT) continues in clinical practice, but reports are conflicting concerning the longer-term breast cancer effects of relatively short-term use...
  69. ncbi request reprint Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    J Clin Oncol 22:4507-13. 2004
    ..However, there are few data on the relative contribution of physical activity, caloric intake, and BMI to fasting insulin levels...
  70. ncbi request reprint Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502 2004, USA
    Clin Breast Cancer 6:S58-64. 2006
    ..If remaining issues are to be addressed, more rigorous CHD and stroke assessment procedures are needed in future trials evaluating AIs...
  71. doi request reprint Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer
    Karen W Kwan
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Clin Breast Cancer 9:219-24. 2009
    ....
  72. doi request reprint Walking speed, physical activity, and breast cancer in postmenopausal women
    Karen Kwan
    aDepartment of Medicine, Kaiser Foundation Hospital Sunset, Los Angeles bLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California cFred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, Washington dDepartment of Social and Prevention Medicine, School of Public Health and Health Professions, University of Buffalo, Buffalo eDepartment of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook fDepartment of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, New York gDepartment of Medicine, George Washington University, Washington, District of Columbia hDepartment of Geriatric Medicine, John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii iDepartment of Behavioral Science, Yale School of Public Health, New Haven, Connecticut, USA
    Eur J Cancer Prev 23:49-52. 2014
    ..Our findings do not support use of timed walking speed as an objective surrogate for self-reported physical activity. ..
  73. ncbi request reprint Vitamin D and breast cancer incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Anticancer Agents Med Chem 13:98-106. 2013
    ..However, a full-scale randomized trial evaluating the influence of vitamin D supplementation on breast cancer recurrence is likely not feasible...
  74. ncbi request reprint Adherence to endocrine therapy for breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502 2064, USA
    Oncology 71:1-9. 2006
    ..Therefore, we reviewed the published literature regarding hormonal therapy adherence in clinical trial and practice settings...
  75. doi request reprint Adherence to oral endocrine therapy for breast cancer: a nursing perspective
    Christine Miaskowski
    Department of Physiological Nursing, University of California, San Francisco, CA, USA
    Clin J Oncol Nurs 12:213-21. 2008
    ..This article summarizes the issues surrounding adherence, paying specific attention to adjuvant endocrine therapy for breast cancer, and outlines strategies to reduce nonadherence that nurses can incorporate into clinical practice...
  76. ncbi request reprint Ethnicity and breast cancer: factors influencing differences in incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Building J 3, Torrance, CA 90502, USA
    J Natl Cancer Inst 97:439-48. 2005
    ..The influence of breast cancer risk factors on these differences has received little attention...
  77. doi request reprint Bisphosphonates and breast cancer incidence and recurrence
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Breast Dis 33:93-101. 2011
    ..Ongoing breast cancer adjuvant clinical trials are further evaluating bisphosphonates and, by their influence on contralateral cancers, may provide more evidence regarding the potential of bisphosphonates for breast cancer prevention...
  78. doi request reprint Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer
    Rowan T Chlebowski
    Division of Medical Oncology and Hematology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Harbor UCLA Medical Center, 1000 W Carson Street, Torrance, CA 90502, USA
    Breast Cancer Res Treat 112:25-34. 2008
    ..Available evidence supports a hypothesis that upfront adjuvant AI therapy is the most appropriate treatment strategy for postmenopausal patients with HR+ disease. Definitive evidence awaits results from ongoing randomized trials...
  79. ncbi request reprint Estrogen plus progestin and colorectal cancer in postmenopausal women
    Rowan T Chlebowski
    Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, Calif 90502, USA
    N Engl J Med 350:991-1004. 2004
    ..We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants...
  80. ncbi request reprint HT and breast cancer risk
    Michelle L Geller
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    Fertil Steril 80:5-9; quiz 54-5. 2003
    ....
  81. ncbi request reprint Bisphosphonates and breast cancer prevention
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, 1124 W Carson St Torrance, CA 90502, USA
    Anticancer Agents Med Chem 12:144-50. 2012
    ..Such reports require cautious interpretation because confounding by indication is an issue: bisphosphonates are prescribed for women with low bone mineral density, and women with low bone density are at decreased breast cancer risk...
  82. pmc Oral bisphosphonate use and risk of postmenopausal endometrial cancer
    Polly A Newcomb
    Polly A Newcomb, Michael N Passarelli, Amanda I Phipps, and Garnet L Anderson, Fred Hutchinson Cancer Research Center Polly A Newcomb, Michael N Passarelli, Amanda I Phipps, and Garnet L Anderson, School of Public Health, University of Washington, Seattle, WA Jean Wactawski Wende, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo Gloria Y F Ho, Albert Einstein College of Medicine, Bronx, NY Mary Jo O Sullivan, University of Miami, Miami, FL and Rowan T Chlebowski, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, CA
    J Clin Oncol 33:1186-90. 2015
    ..This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer...
  83. ncbi request reprint Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study
    Rowan T Chlebowski
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson St, Building J 3, Torrance, CA 90502 2064, USA
    J Natl Cancer Inst 98:1767-76. 2006
    ..We carried out a randomized, prospective, multicenter clinical trial to test the effect of a dietary intervention designed to reduce fat intake in women with resected, early-stage breast cancer receiving conventional cancer management...
  84. ncbi request reprint Menopausal hormone therapy after breast cancer
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    Lancet 363:410-1. 2004
  85. pmc Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey
    Katherine D Nguyen
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Med Internet Res 7:e28. 2005
    ..While information websites have been developed by major cancer organizations, their appropriateness for patients in multiethnic, multilingual public hospital settings has received limited attention...
  86. doi request reprint Translating trial data into patients benefits: making the right choice
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, Building J 3, Torrance, CA 90502, USA
    Breast 17:S9-15. 2008
    ..Therefore, using an AI at the earliest opportunity provides patients with the best option to prevent the recurrence and excess adverse events associated with tamoxifen...
  87. ncbi request reprint Early breast and prostate cancer and clinical outcomes (fracture)
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, California, USA
    Oncology (Williston Park) 23:16-20. 2009
    ..Strategies for management of bone loss in breast and prostate cancer are outlined by guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network...
  88. ncbi request reprint Weight loss in breast cancer patient management
    Rowan T Chlebowski
    Harbor University of California Los Angeles Research and Education Institute, Torrance, CA 90502, USA
    J Clin Oncol 20:1128-43. 2002
    ..To systematically review and summarize evidence relevant to obesity and breast cancer clinical outcome, potential hormonal mediating mechanisms, and the current status of weight loss interventions for chronic disease management...
  89. ncbi request reprint Abnormal mammographic findings with short-interval follow-up recommendation
    Rowan T Chlebowski
    Department of Medicine, Division of Medical Oncology and Hematology, Los Angeles BioMedical Research Institute and Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    Clin Breast Cancer 6:235-9. 2005
    ..Given the potential psychologic impact of abnormal mammographic results, studies attempting to more accurately relate screening mammography findings to breast cancer risk are a priority...
  90. doi request reprint Menopausal hormone therapy, hormone receptor status, and lung cancer in women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Semin Oncol 36:566-71. 2009
    ..In addition, the findings, together with ongoing studies evaluating estrogen receptor status and function, support further efforts to develop lung cancer intervention strategies targeting estrogen receptor expression...
  91. ncbi request reprint Bone health in women with early-stage breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Building J 3, Torrance, CA 90502, USA
    Clin Breast Cancer 5:S35-40. 2005
    ..Current information suggests bone loss associated with estrogen reduction in breast cancer survivors may represent a preventable and treatable condition. Ongoing clinical trials will definitively evaluate this hypothesis...
  92. doi request reprint Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial
    Rowan T Chlebowski
    Division of Medical Oncology and Hematology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Clin Breast Cancer 8:343-6. 2008
    ....
  93. doi request reprint Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Clin Trials 7:744-8. 2010
    ..To evaluate two recruitment strategies used during the full-scale randomized, placebo-controlled Selenium and Vitamin E Cancer Prevention Trial (SELECT) at one clinical center...
  94. ncbi request reprint Research staff turnover and participant adherence in the Women's Health Initiative
    Marie Jackson
    Harbor UCLA Research and Education Institute, Torrance, California 90502 2064, USA
    Control Clin Trials 24:422-35. 2003
    ..Further prospective study exploring process evaluation of the provider side of controlled trial conduct is indicated...
  95. pmc Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer
    Brigette L Tippin
    Division of Medical Genetics, Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Prostaglandins Other Lipid Mediat 97:22-8. 2012
    ..Other approaches will be needed to establish a role for HPGDS in occurrence of human intestinal tumors, as indicated by a mouse model...
  96. ncbi request reprint Management of bloody nipple discharge
    Hernan I Vargas
    Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, 1000 W Carson Street, Box 25, Torrance, CA 90502, USA
    Curr Treat Options Oncol 3:157-61. 2002
    ..The early success reported with image-guided excision of papilloma and duct endoscopy promises a significant improvement in our diagnostic accuracy from minimally invasive emerging technology...